This announcement details the progress of a related party transaction where Repro Bio-Pharmaceutical Co., Ltd. acquired a 30% stake in its subsidiary, Tianjin China Supply Chain Management Co., Ltd. The transaction, valued at RMB 65.865 million, has completed its registration process. The equity structure has been updated to reflect Repro Bio-Pharmaceutical's increased ownership.
Summary generated by AI · Always verify with source document
Repro Bio-Pharmaceutical Co., Ltd.
Announcement on Progress of Related Party Transaction for Acquisition of Partial Equity in Tianjin China Supply Chain Management Co., Ltd.
The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or significant omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.